1. N Engl J Med; Volume 373(17):1627-1639; October 22, 2015
R3 이지훈 / Prof. 백선경

2. BACKGROUND 2nd line treatment for advanced NSCLC
Docetaxel : anti-mitotics
Pemetrexed (Alimta) : folate antimetabolites
Erlotinib (Tarceva) : EGFR inhibitor

3. BACKGROUND Nivolumab a fully human IgG4 anti-PD-1 monoclonal Ab
“Cancer Immunotherapy”
Restore antitumor immunity
In phase 1 studies
Durable antitumor activity
Encouraging results on survival in all NSCLC subtypes
Response rate : 17.6%
Overall survival : 42%(1yr) → 23%(2yrs) → 16%(3yrs)
Progression-free survival : 18% at 1 year

5. BACKGROUND

6. METHODS

9. RESULTS

12. RESULTS

13. RESULTS

15. CONCLUSION
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel.